COMPOSITIONS AND METHODS FOR INHIBITING THE ACTIVITY OF P110a MUTANT PROTEINS
AssigneeCase Western Reserve University
InventorsZhengne Wang, Yujun Hao, Chao Wang, Weiping Zheng
Life of this patent
Estimating the term…
Abstract
A method of inhibiting the activity, signaling, and/or function of a p110α mutant protein in a cancer cell expressing the p110α mutant protein includes administering to the cancer cell an amount of a therapeutic agent effective to inhibit binding of the p110α mutant protein to IRS1 in the cell.
Claims22
A method of inhibiting the activity, signaling, and/or function of a p110α mutant protein in a cancer cell expressing the p110α mutant protein, the method comprising administering to the cancer cell an amount of a therapeutic agent effective to inhibit binding of the p110α mutant protein to IRS1 in the cell, the therapeutic agent comprising a polypeptide consisting of about 10 to about 40 amino acids, the polypeptide having at 80% sequence identity with consecutive amino acids of a portion of a helical domain of the p110α mutant protein that includes the mutated amino acid.
A method of treating cancer in a subject, the cancer including cancer cells expressing a p110α mutant protein, the method comprising:
- administering to the cancer cells expressing the p110α mutant protein a therapeutically effective amount of an agent that inhibits binding of a p110α mutant protein to IRS1 in the cancer cells, the therapeutic agent comprising a polypeptide consisting of about 10 to about 40 amino acids, the polypeptide having at 80% sequence identity with consecutive amino acids of a portion of a helical domain of the p110α mutant protein that includes the mutated amino acid.
A method of treating cancer in a subject, the cancer including cancer cells expressing a p110α mutant protein, the method comprising:
- administering to the cancer cells expressing the p110α mutant protein a therapeutically effective amount of an agent that inhibits binding of a p110α mutant protein to IRS1 in the cancer cells, the therapeutic agent comprising a polypeptide consisting of about 10 to about 40 amino acids, the polypeptide having at 90% sequence identity with consecutive amino acids of a portion of a helical domain of the p110α mutant protein that includes the mutated amino acid selected from the group consisting of a E545K, E542K, E545A, E545G or Q546K.
Dependencies are inferred from the claim text.